Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMS NASDAQ:ANIX NASDAQ:APVO NASDAQ:CBIO NASDAQ:NERV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMSAdamas Pharmaceuticals$8.22$8.17$4.02▼$9.15$376.37M2.82692,487 shsN/AANIXAnixa Biosciences$3.14-2.2%$2.98$2.07▼$4.20$101.14M0.39104,481 shs65,863 shsAPVOAptevo Therapeutics$3.10+6.9%$5.45$2.81▼$485.37$2.36M5.58606,935 shs209,376 shsCBIOCrescent Biopharma$15.09-1.3%$0.00$11.06▼$63.00$295.01M1.5224,533 shs114,029 shsNERVMinerva Neurosciences$1.63-0.6%$1.67$1.15▼$3.50$11.40M-0.3422,799 shs5,823 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMSAdamas Pharmaceuticals0.00%0.00%0.00%0.00%0.00%ANIXAnixa Biosciences-4.18%-2.73%+16.30%+34.87%+40.17%APVOAptevo Therapeutics-3.97%-4.92%-41.41%-85.64%-99.96%CBIOCrescent Biopharma-3.78%-5.27%-98.01%-98.01%-98.01%NERVMinerva Neurosciences-3.53%-4.65%-10.33%+23.31%-47.10%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AANIXAnixa Biosciences2.6535 of 5 stars3.63.00.00.01.13.30.0APVOAptevo Therapeutics2.1053 of 5 stars3.53.00.00.00.60.01.3CBIOCrescent Biopharma3.3037 of 5 stars3.80.00.03.72.51.70.6NERVMinerva Neurosciences3.9443 of 5 stars3.04.00.04.60.90.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMSAdamas Pharmaceuticals 0.00N/AN/AN/AANIXAnixa Biosciences 3.25Buy$9.00186.62% UpsideAPVOAptevo Therapeutics 3.00Buy$219,040.007,065,706.45% UpsideCBIOCrescent Biopharma 3.67Strong Buy$25.0065.67% UpsideNERVMinerva Neurosciences 2.00Hold$5.00206.75% UpsideCurrent Analyst Ratings BreakdownLatest NERV, APVO, ADMS, CBIO, and ANIX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/25/2025CBIOCrescent BiopharmaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$28.006/20/2025CBIOCrescent BiopharmaTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy6/18/2025CBIOCrescent BiopharmaLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$22.006/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/29/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.004/10/2025ANIXAnixa BiosciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMSAdamas Pharmaceuticals$74.46M5.05N/AN/A($0.47) per share-17.49ANIXAnixa Biosciences$210K481.62N/AN/A$0.59 per share5.32APVOAptevo Therapeutics$3.11M0.76N/AN/A$65.21 per share0.05CBIOCrescent Biopharma$10K29,500.95N/AN/A$8.24 per share1.83NERVMinerva NeurosciencesN/AN/A$0.21 per share7.90($3.67) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMSAdamas Pharmaceuticals-$57.40M-$1.70N/AN/AN/A-71.11%N/A-42.96%N/AANIXAnixa Biosciences-$12.55M-$0.38N/A∞N/AN/A-68.17%-60.38%9/5/2025 (Estimated)APVOAptevo Therapeutics-$24.13MN/A0.00N/AN/AN/A-779.42%-175.59%8/6/2025 (Estimated)CBIOCrescent Biopharma-$37.88M-$46.00N/AN/AN/AN/A-293.92%-206.20%N/ANERVMinerva Neurosciences$1.44M$0.821.99N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)Latest NERV, APVO, ADMS, CBIO, and ANIX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A6/3/2025Q2 2025ANIXAnixa Biosciences-$0.10-$0.09+$0.01-$0.09N/AN/A5/15/2025Q1 2025APVOAptevo Therapeutics-$84.20-$87.80-$3.60-$4.39N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMSAdamas PharmaceuticalsN/AN/AN/AN/AN/AANIXAnixa BiosciencesN/AN/AN/AN/AN/AAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACBIOCrescent BiopharmaN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMSAdamas Pharmaceuticals21.254.534.17ANIXAnixa BiosciencesN/A8.898.89APVOAptevo TherapeuticsN/A0.670.67CBIOCrescent BiopharmaN/A2.292.29NERVMinerva NeurosciencesN/A9.219.21Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMSAdamas Pharmaceuticals69.97%ANIXAnixa Biosciences29.13%APVOAptevo Therapeutics8.06%CBIOCrescent Biopharma75.19%NERVMinerva Neurosciences34.56%Insider OwnershipCompanyInsider OwnershipADMSAdamas Pharmaceuticals18.90%ANIXAnixa Biosciences25.30%APVOAptevo Therapeutics0.12%CBIOCrescent Biopharma8.70%NERVMinerva Neurosciences8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMSAdamas Pharmaceuticals13845.79 million37.13 millionOptionableANIXAnixa Biosciences532.21 million24.06 millionOptionableAPVOAptevo Therapeutics50760,000755,000Not OptionableCBIOCrescent Biopharma5019.55 million17.85 millionNo DataNERVMinerva Neurosciences96.99 millionN/ANot OptionableNERV, APVO, ADMS, CBIO, and ANIX HeadlinesRecent News About These CompaniesFire destroys popular North Nashville nightclub Minerva AvenueJuly 6 at 6:32 AM | msn.comMinerva nights event to include music, food, gamesJune 27, 2025 | cantonrep.comCNordic Capital invests in CRO and CDMO Minerva ImagingJune 11, 2025 | pehub.comMinerva Neurosciences, Inc: Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 14, 2025 | finanznachrichten.deMinerva Neurosciences Reports First Quarter 2025 Financial Results and Business UpdatesMay 13, 2025 | globenewswire.comMinerva Neurosciences Inc.April 23, 2025 | barrons.comMinerva Neurosciences regains Nasdaq complianceMarch 21, 2025 | investing.comMinerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business UpdatesFebruary 25, 2025 | globenewswire.comMinerva Neurosciences stock hits 52-week low at $2.02February 12, 2025 | msn.comMinerva Neurosciences Stock Hits 52-Week Low at $2.03January 22, 2025 | msn.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 6, 2024 | markets.businessinsider.comMinerva Neurosciences Reports Third Quarter 2024 Financial Results and Business UpdatesNovember 5, 2024 | globenewswire.com'It has meant everything': Minerva girls win second straight cross country state titleNovember 4, 2024 | msn.comMinerva Fabienne Hase and Nikita Volodin of Germany sit in top spot after pairs shortNovember 2, 2024 | msn.comUS to Overtake China as Top Beef Importer From Brazil’s MinervaOctober 31, 2024 | bloomberg.comCommunity Conversations: El Paso Sheriff candidate Minerva Torres SheltonOctober 29, 2024 | msn.comNeuroscientist, Musician, and Author Dr. Daniel Levitin Talks New Book ‘I Heard There Was a Secret Chord: Music as Medicine’ and More (INTERVIEW)October 28, 2024 | glidemagazine.comGPotential ingredient to prevent hyperpigmentation after being treated for varicose veinsOctober 28, 2024 | labroots.comLMinerva chamber member honored as 'Bright Star'October 28, 2024 | yahoo.comHigh school cross country: Minerva sweeps boys and girls district titles againOctober 21, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNERV, APVO, ADMS, CBIO, and ANIX Company DescriptionsAdamas Pharmaceuticals NASDAQ:ADMSAdamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.Anixa Biosciences NASDAQ:ANIX$3.14 -0.07 (-2.18%) Closing price 04:00 PM EasternExtended Trading$3.22 +0.07 (+2.39%) As of 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.Aptevo Therapeutics NASDAQ:APVO$3.10 +0.20 (+6.90%) Closing price 04:00 PM EasternExtended Trading$3.03 -0.07 (-2.26%) As of 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Crescent Biopharma NASDAQ:CBIO$15.09 -0.20 (-1.31%) As of 04:00 PM EasternCrescent Biopharma, Inc. operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.Minerva Neurosciences NASDAQ:NERV$1.63 -0.01 (-0.61%) Closing price 04:00 PM EasternExtended Trading$1.67 +0.04 (+2.45%) As of 05:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.